EGFR and breast carcinoma: Zhang lab engineered an interesting exosome‐based nanoformulation named SMART‐Exos (synthetic multivalent antibodies retargeted exosomes, Figure 7a),[93] which were derived from genetically edited HEK293 cells expressing anti EGFR and anti‐CD3 mAbs to link T cells and EGFR‐expressing MDA‐MB‐468 human breast cancer cells (Figure 7b).